Clinical Trial Update: Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of rituximab plus gemcitabine for relapsed or refractory diffuse large B-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Rituximab (rituximab)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Lymphoma, B-Cell | Phase 2 | Status: TERMINATED